- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01845792
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
Phase II Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel, Compared to Cabazitaxel Alone, in Patients With Metastatic Castrate Resistant Prostate Cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent has been obtained.
- Adults over 18 years of age.
- Histologically or cytologically proven adenocarcinoma of the prostate.
- Stage IV disease as evidenced by soft tissue, visceral and/or bony metastasis must be Response Evaluation Criteria in Solid Tumors (RECIST) evaluable on CT scan and/or bone scan
Progressive disease while receiving hormonal therapy or after surgical castration documented by at least one of the following:
- Increase in measurable disease per RECIST 1.1,
- Appearance of new lesions on bone scan consistent with progressive prostate cancer (>2 new lesions on bone scans if this is the only measure of PD),
rising PSA defined as 2 sequential increases above a previous lowest reference value.
- Each value must be obtained at least 1 week apart.
- PSA at least 2 ng/mL
- Received prior docetaxel chemotherapy
- Received prior abiraterone acetate, but not within the 3 months prior to study drug dosing.
- Testosterone level <50 ng/mL. Patients receiving Leutinizing Hormone Releasing Hormone (LHRH) agonists or antagonists must be continued to maintain castrate levels of testosterone while on study.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
Adequate hematologic function:
- platelet >100, 000/uL;
- neutrophil count of >1500 cell/mm3;
- hemoglobin >9.0 g/dL)
- Adequate renal function (Creatinine clearance > 50 mL/min)
- Adequate potassium level (> 3.5 mEq/dL)
Adequate hepatic function
- bilirubin < 1.5 X upper limit of normal (ULN),
- alanine aminotransferase (ALT) < 1.5 X ULN,
- aspartate aminotransferase (AST) < 1.5 X ULN.
- serum albumin of ≥ 3.0 g/dL.
- Controlled blood pressure, defined as blood pressure ≤ 140/90 on average (3 separate readings taken at screening visit in a relaxed clinical environment and averaged)
- Must be able to take oral medication without crushing, dissolving or chewing tablets
Willing to take abiraterone acetate on empty stomach;
(1) no food should be consumed at least two hours before and for at least one hour after the dose of abiraterone acetate is taken.
- Patients must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.
- Written authorization for use and release of health and research study information has been obtained.
- Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection during the study and for 1 week after the last dose of abiraterone acetate.
Exclusion Criteria:
- Surgery or radiation therapy within 2 weeks, or
- Cytotoxic anti-cancer therapy within 3 weeks, or
- Non-cytotoxic anti-cancer therapy within 2 weeks, or 5 half-lives (whichever is shorter) of Study Day 1.
- Prior radiotherapy to ≥ 40% of bone marrow.
- Prior treatment with Radium 223.
- Use of an investigational therapeutic agent within 30 days.
- Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents.
- Prior treatment with cabazitaxel.
- Known chronic infection with human immunodeficiency virus (HIV).
- Known active, or symptomatic, brain metastasis.
- Blood pressure >140/90 on average (3 separate readings taken at screening visit in a relaxed clinical environment and averaged).
- History of autoimmune disorder requiring daily corticosteroid therapy of greater than prednisone 10mg daily, or its equivalent.
- Baseline peripheral edema > grade 3.
- Pre-existing diarrhea uncontrolled with supportive care;
- Prior hemorrhagic diarrhea due to ulcerative colitis, inflammatory bowel disease or other cause;
- Active, uncontrolled peptic ulcer disease even in the setting of proton-pump inhibitor or Histamine2-blocker use.
- Pre-existing peripheral neuropathy grade > 2.
- Documented hypersensitivity (CTCAE grade > 2) to any drug containing polysorbate 80.
- Have known allergies or hypersensitivity to abiraterone acetate or prednisone or their excipients.
- Contraindications to steroid use.
- Need for medications that strongly induce or inhibit cytochrome P450 3A4 (CYP3A4) or cytochrome P450 2D6 (CYP2D6) activity. (see section 7.2.3 for details)
- Serious infection requiring parenteral antibiotics within 14 days of enrollment.
- Poorly controlled diabetes (Hgb A1C >9).
- Active or symptomatic viral hepatitis or Chronic liver disease, including Child-Pugh Class B and C liver disease.
- History of pituitary or adrenal dysfunction.
Clinically significant heart disease as evidenced by:
- myocardial infarction, or
- arterial thrombotic events in the past 6 months,
- severe or unstable angina, or
- New York Heart Association Class III-IV heart disease, or
- cardiac ejection fraction measurement of <50% at baseline.
- Consumption of food or beverages containing grapefruit juice within 7 days of study drug dosing
Use of a first-generation anti-androgen such as:
- bicalutamide within 6 weeks of study drug dosing, or
- flutamide within 4 weeks of study dosing.
- Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cabazitaxel with Abiraterone Acetate
Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.
|
Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
Other Names:
|
ACTIVE_COMPARATOR: Cabazitaxel Alone
Cabazitaxel administered as a single intravenous dose every 3 weeks
|
Cabazitaxel intravenously every 3 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival
Time Frame: 3 months
|
Progression-free survival at 3 months.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PSA Response
Time Frame: 2 years
|
Prostate specific antigen (PSA) decline by 50% or more from baseline.
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Abiraterone Acetate
Other Study ID Numbers
- 13-1489.cc
- NCI-2013-01356 (OTHER: National Cancer Institute)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Cabazitaxel with Abiraterone Acetate
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
University Health Network, TorontoCompleted
-
Cougar Biotechnology, Inc.Completed
-
Jiangnan UniversityAffiliated Hospital of Jiangnan UniversityRecruitingCastration-resistant Prostate CancerChina
-
The Netherlands Cancer InstituteCompletedMetastasis | Prostate Cancer MetastaticNetherlands
-
Janssen Research & Development, LLCCompleted
-
Cougar Biotechnology, Inc.Completed
-
Cougar Biotechnology, Inc.Completed
-
Cougar Biotechnology, Inc.CompletedProstate NeoplasmsUnited Kingdom, United States
-
SanofiTerminated